Ordspono
What Ordspono is used for
Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL) after two or more lines of systemic therapy. Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after two or more lines of systemic therapy.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Conditional approval: approved on less complete data because the need is high; more data must follow.
Key facts
- Brand
- Ordspono
- Active substance
- odronextamab
- Disease area
- Lymphoma, Follicular
- Medicine group
- Antineoplastic agents
- ATC code
- Not yet assigned
- Marketing authorisation holder
- Regeneron Ireland Designated Activity Company (DAC)
- Authorised in the EU since
- 2024
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ordspono used for?
Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL) after two or more lines of systemic therapy. Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after two or more lines of systemic therapy.
What is the active substance in Ordspono?
Ordspono contains odronextamab.
Who makes Ordspono?
The EU marketing authorisation holder is Regeneron Ireland Designated Activity Company (DAC).
Is Ordspono an orphan medicine?
Yes. Ordspono is designated an orphan medicine in the EU, for a rare disease (Lymphoma, Follicular).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU